The Genotype for DPYD Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice

Giuseppe Toffoli, Federico Innocenti, Jerry Polesel, Elena De Mattia, Franca Sartor, Chiara Dalle Fratte, Fabrizio Ecca, Eva Dreussi, Elisa Palazzari, Michela Guardascione, Angela Buonadonna, Luisa Foltran, Marica Garziera, Alessia Bignucolo, Stefania Nobili, Enrico Mini, Adolfo Favaretto, Massimiliano Berretta, Mario D'Andrea, Antonino De PaoliRossana Roncato, Erika Cecchin

Research output: Contribution to journalArticle

Abstract

Lack of information on the clinical utility of preemptive DPYD screening before fluoropyrimidine treatment is a major barrier preventing its use in clinical practice. This study aimed to define the association between DPYD variants and fluoropyrimidine-related toxicity management costs. A cost analysis was conducted on the toxicities experienced by 550 patients with colorectal cancer treated with fluoropyrimidine-based chemotherapy. Genotyping for DPYD*2A, DPYD*13, DPYDc. 2846A>T, DPYD-HapB3, and UGT1A1*28 was done retrospectively and did not affect patients’ treatments. Carriers of at least one DPYD variant experienced higher toxicity management costs (€2,972; 95% confidence interval (CI), €2,456–€3,505) than noncarriers (€825; 95% CI, €785–€864) (P < 0.0001) and had a higher risk for toxicity requiring hospitalization (odds ratio, 4.14; 95% CI, 1.87–9.14). In patients receiving fluoropyrimidine/irinotecan, the incremental cost between DPYD variant and UGT1A1*28/*28 carriers and noncarriers was €2,975. This study suggests that the toxicity management costs during fluoropyrimidine-based therapy are associated with DPYD and UGT1A1*28 variants and supports the utility of genotyping.

Original languageEnglish
JournalClinical Pharmacology and Therapeutics
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Colorectal Neoplasms
Genotype
Costs and Cost Analysis
irinotecan
Confidence Intervals
Hospitalization
Therapeutics
Odds Ratio
Drug Therapy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

The Genotype for DPYD Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice. / Toffoli, Giuseppe; Innocenti, Federico; Polesel, Jerry; De Mattia, Elena; Sartor, Franca; Dalle Fratte, Chiara; Ecca, Fabrizio; Dreussi, Eva; Palazzari, Elisa; Guardascione, Michela; Buonadonna, Angela; Foltran, Luisa; Garziera, Marica; Bignucolo, Alessia; Nobili, Stefania; Mini, Enrico; Favaretto, Adolfo; Berretta, Massimiliano; D'Andrea, Mario; De Paoli, Antonino; Roncato, Rossana; Cecchin, Erika.

In: Clinical Pharmacology and Therapeutics, 01.01.2018.

Research output: Contribution to journalArticle

@article{51bfd630915b4bce87793dd162ebf4fc,
title = "The Genotype for DPYD Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice",
abstract = "Lack of information on the clinical utility of preemptive DPYD screening before fluoropyrimidine treatment is a major barrier preventing its use in clinical practice. This study aimed to define the association between DPYD variants and fluoropyrimidine-related toxicity management costs. A cost analysis was conducted on the toxicities experienced by 550 patients with colorectal cancer treated with fluoropyrimidine-based chemotherapy. Genotyping for DPYD*2A, DPYD*13, DPYDc. 2846A>T, DPYD-HapB3, and UGT1A1*28 was done retrospectively and did not affect patients’ treatments. Carriers of at least one DPYD variant experienced higher toxicity management costs (€2,972; 95{\%} confidence interval (CI), €2,456–€3,505) than noncarriers (€825; 95{\%} CI, €785–€864) (P < 0.0001) and had a higher risk for toxicity requiring hospitalization (odds ratio, 4.14; 95{\%} CI, 1.87–9.14). In patients receiving fluoropyrimidine/irinotecan, the incremental cost between DPYD variant and UGT1A1*28/*28 carriers and noncarriers was €2,975. This study suggests that the toxicity management costs during fluoropyrimidine-based therapy are associated with DPYD and UGT1A1*28 variants and supports the utility of genotyping.",
author = "Giuseppe Toffoli and Federico Innocenti and Jerry Polesel and {De Mattia}, Elena and Franca Sartor and {Dalle Fratte}, Chiara and Fabrizio Ecca and Eva Dreussi and Elisa Palazzari and Michela Guardascione and Angela Buonadonna and Luisa Foltran and Marica Garziera and Alessia Bignucolo and Stefania Nobili and Enrico Mini and Adolfo Favaretto and Massimiliano Berretta and Mario D'Andrea and {De Paoli}, Antonino and Rossana Roncato and Erika Cecchin",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/cpt.1257",
language = "English",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - The Genotype for DPYD Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice

AU - Toffoli, Giuseppe

AU - Innocenti, Federico

AU - Polesel, Jerry

AU - De Mattia, Elena

AU - Sartor, Franca

AU - Dalle Fratte, Chiara

AU - Ecca, Fabrizio

AU - Dreussi, Eva

AU - Palazzari, Elisa

AU - Guardascione, Michela

AU - Buonadonna, Angela

AU - Foltran, Luisa

AU - Garziera, Marica

AU - Bignucolo, Alessia

AU - Nobili, Stefania

AU - Mini, Enrico

AU - Favaretto, Adolfo

AU - Berretta, Massimiliano

AU - D'Andrea, Mario

AU - De Paoli, Antonino

AU - Roncato, Rossana

AU - Cecchin, Erika

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Lack of information on the clinical utility of preemptive DPYD screening before fluoropyrimidine treatment is a major barrier preventing its use in clinical practice. This study aimed to define the association between DPYD variants and fluoropyrimidine-related toxicity management costs. A cost analysis was conducted on the toxicities experienced by 550 patients with colorectal cancer treated with fluoropyrimidine-based chemotherapy. Genotyping for DPYD*2A, DPYD*13, DPYDc. 2846A>T, DPYD-HapB3, and UGT1A1*28 was done retrospectively and did not affect patients’ treatments. Carriers of at least one DPYD variant experienced higher toxicity management costs (€2,972; 95% confidence interval (CI), €2,456–€3,505) than noncarriers (€825; 95% CI, €785–€864) (P < 0.0001) and had a higher risk for toxicity requiring hospitalization (odds ratio, 4.14; 95% CI, 1.87–9.14). In patients receiving fluoropyrimidine/irinotecan, the incremental cost between DPYD variant and UGT1A1*28/*28 carriers and noncarriers was €2,975. This study suggests that the toxicity management costs during fluoropyrimidine-based therapy are associated with DPYD and UGT1A1*28 variants and supports the utility of genotyping.

AB - Lack of information on the clinical utility of preemptive DPYD screening before fluoropyrimidine treatment is a major barrier preventing its use in clinical practice. This study aimed to define the association between DPYD variants and fluoropyrimidine-related toxicity management costs. A cost analysis was conducted on the toxicities experienced by 550 patients with colorectal cancer treated with fluoropyrimidine-based chemotherapy. Genotyping for DPYD*2A, DPYD*13, DPYDc. 2846A>T, DPYD-HapB3, and UGT1A1*28 was done retrospectively and did not affect patients’ treatments. Carriers of at least one DPYD variant experienced higher toxicity management costs (€2,972; 95% confidence interval (CI), €2,456–€3,505) than noncarriers (€825; 95% CI, €785–€864) (P < 0.0001) and had a higher risk for toxicity requiring hospitalization (odds ratio, 4.14; 95% CI, 1.87–9.14). In patients receiving fluoropyrimidine/irinotecan, the incremental cost between DPYD variant and UGT1A1*28/*28 carriers and noncarriers was €2,975. This study suggests that the toxicity management costs during fluoropyrimidine-based therapy are associated with DPYD and UGT1A1*28 variants and supports the utility of genotyping.

UR - http://www.scopus.com/inward/record.url?scp=85056807371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056807371&partnerID=8YFLogxK

U2 - 10.1002/cpt.1257

DO - 10.1002/cpt.1257

M3 - Article

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

ER -